Kornimate/medical-research-clean huggingface dataset:
axios™ gastroenterostomy for gastric outlet obstruction ide

Conditions: Gastric Outlet Obstruction

Summary: to investigate the safety and technical success of eus-guided gastroenterostomy (eus-ge) using the axiostm lumen-apposing metal stent for the management of symptoms associated with gastric outlet obstruction from malignant unresectable neoplasm.

the study is a prospective multi-center, single -arm study with treatment of up to 67 subjects at up to 10 clinical centers. subjects who meet all eligibility criteria will receive the axios stent and up to 12 months follow-up.

Eligibility criteria:
inclusion criteria: 1. gastric outlet obstruction from unresectable malignant neoplasm 2. eligible for endoscopic intervention 3. goos of 0 or 1 0 - no oral intake 1 - liquids only 2 - soft solids only 3 - low-residue or full diet 4. 18 years of age or older 5. willing and able to comply with the study procedures or legally authorized representative (lar) must provide written informed consent form (icf) to participate in the study 6. the distance between the gastric lumen and jejunal lumen must be no more than 1.0 cm exclusion criteria: 1. patients with baseline ecog \> 2 and/or karnofsky performance score \< 30 2. gastric cancer or any malignant infiltration precluding a cancer free puncture site of the axiostm stent 3. abnormal coagulation inr \> 1.5 and not correctable (per the discretion of the physician) or who require continuous complete anticoagulation, and/or any underlying condition associated with high risk of bleeding 4. altered anatomy of the upper gastrointestinal tract due to surgery of esophagus, stomach and duodenum that might preclude endoscopic gastroenterostomy 5. multiple-level bowel obstruction downstream from the intended location of the eus-guided bypass confirmed by radiography such as small bowel series or computed tomography 6. presence of intraperitoneal fat between the gastric lumen and jejunal lumen estimated to be larger than 1.0 cm at the proposed site of axiostm stent insertion 7. gastric varices located within a two-centimeter radius of the device insertion location on the gastric wall 8. ascites grade ≥ 2 confirmed by cross-sectional imaging 9. vessels located within a two-centimeter radius of the device insertion location 10. history of multiple abdominal surgeries and/or evidence of small bowel adhesions 11. allergic to any of the device materials 12. contraindications to use of electrical devices 13. pregnancy 14. prisoners and other vulnerable populations

Keywords: goo gastric outlet obstruction axios gastroenterostomy
exploring the effect of interactive board game health education on improving stroke knowledge and health literacy in community-dwelling adults

Conditions: Stroke

Summary: the purpose of this study is to explore the effectiveness between interactive board game health education and conventional health education in improving community-dwelling adults' stroke knowledge and self-reported stroke health literacy, including risk factors, symptoms, acute management of stroke, and 6 aspects of self-reported stroke health literacy. the intervention group will receive an interactive board game in a group (2\~6 individuals), while the control group was assigned to read the health education flier and watching the stroke prevention video. the follow-up period was set to be four weeks after the intervention, both control group, and intervention group.

stroke is a major health problem and a known cause of death and disability. approximately 13 million people suffered from stroke worldwide annually and it ranks fourth among the top 10 causes of death in taiwan. in a recent survey of taiwanese citizens on the world stroke day event (new taipei city) in 2012, the public's stroke literacy was low, only 5.71% of them can reach "good stroke literacy". generally, stroke education was mostly implemented in a one-way lecture way. therefore, instead of one-way style health education, the investigators assume that interactive board games can increase stroke knowledge, stroke literacy, and self-reported stroke health literacy of community-dwelling seniors.

Eligibility criteria:
inclusion criteria: * aged 50 years old or above. * cases with sanity and ability to communicate in chinese or taiwanese. * no oral difficulties in daily life, able to fully express research-relevant narratives and readings. exclusion criteria: * patients with a history of stroke diagnosed by a physician. * non-republic of china (taiwan) nationality. * worked as a medical staff in the past, in the fields of medical care or health educator. * those who cannot complete the assessment according to the guidance of the assessor.
improving patient outcomes by selective implantation of the zephyr ebv - study

Conditions: COPD Patients With Homogeneous Emphysema; Endoscopic Lung Volume Reduction With Endobronchial Valve

Summary: the aim of this prospective, randomized, controlled, one-way crossover study is to assess and compare the efficacy of the zephyr endobronchial valves vs. standard of care (soc) in patients suffering from copd with homogeneous emphysema. patients will be followed up for 12 months after randomization. patients in the soc arm will crossover to the ebv treatment arm after the 6-month visit and will be followed up for 6 additional months.the primary objective is the variation of fev1 between baseline and 3-month follow-up visit. the secondary objectives will evaluate quality of life, exercise capacity, dyspnea (including bode index) changes, target lobe volume reduction, as well as safety outcomes.


Eligibility criteria:
inclusion criteria: * homogeneous emphysema * 15% ≤ fev1 ≤ 45% predicted * tlc \> 100% predicted * rv ≥ 200% predicted * 6mwt ≥ 150 m * non-smoker \> 8 weeks prior to study entry * absence of collateral ventilation in the target lobe exclusion criteria: * active pulmonary infection * more than 3 exacerbations with hospitalizations over the past 12 months * pulmonary hypertension (spap \> 45 mmhg) * mi or other relevant cv events in the past 6 months * alpha-1 antitrypsin deficiency * bronchiectasis * prior lvr or lvrs procedure * \> 20% difference in perfusion between right and left lung * hypercapnia (paco2 \> 55 mmhg * asthma * use of more than 25 mg/day prednisolone or equivalent * severe bullous emphysema * systemic or malignant disease with high death probability within 12 months
rehabilitation of the upper extremity with enhanced proprioceptive feedback following incomplete spinal cord injury

Conditions: Spinal Cord Injury; Tetraplegia; Paresis; Plegia

Summary: the purpose of this study is to determine if tetraplegic individuals with incomplete spinal cord injury (sci) who remain unable to move their arms normally 1 year after their scis are able to sense and move the affected arm(s) better after 10-13 weeks of treatment with a new robotic therapy device. the hypothesis is that using the ames device on the arm(s) of chronic tetraplegic subjects with incomplete sci will result in improved strength, sensation, and functional movement in treated limb(s).

traumatic spinal cord injury (sci) affects over 200,000 people in the usa, with several thousand new injuries each year. most recovery, following sci, occurs in the six months following surgery. further recovery after 12 months is unusual. in this study 13 subjects, more than 1 year post injury, were enrolled to test the safety and efficacy of a new type of robotic therapy device known as the ames device. the aim of this phase i/ii study is to investigate the use of assisted movement and enhanced sensation (ames) technology in hand rehabilitation of incomplete sci subjects.

Eligibility criteria:
inclusion criteria: * traumatic sci with tetraplegia. * male or female. * 18-65 yrs old. * at least 1 yr post-sci. * tolerate sitting upright at for at least one hour. * able to perceive direction of passive joint(s) motion of the upper extremity(ies) to be treated 70% or more of the times tested. * motor grade \>1 in the wrist extensors, finger flexors and finger abductors (the 3 muscles related to hand movements in the asia scale) in the upper extremity tested. * cognitively and behaviorally capable of complying with the regimen. exclusion criteria: * fracture of the treated limb resulting in loss of range of motion * concomitant tbi or stroke (patients who sustained mild head injury during the trauma with no evidence of structural abnormalities on brain images will qualify for the study) * dvt of the treated extremity * peripheral nerve injury of the treated extremity * osteo- or rheumatoid-arthritis limiting range of motion * contractures equal to or greater than 50% of the normal rom * skin condition not tolerant of device * progressive neurodegenerative disorder * botox treatment of the treated extremity in the prior 5 month * chronic itb therapy * uncontrolled seizure disorder * uncontrolled high blood pressure/angina * pain in affected limb or exercise intolerance

Keywords: incomplete spinal cord injury rehabilitation upper extremity ames device incomplete sci quadriplegia
effects of inorganic nitrate and intensity of exercise on cardiovascular health in post-menopausal females

Conditions: Vascular Dilation; Arterial Stiffness

Summary: post-menopausal females experience elevated cardiovascular disease risk (cvd), compared to premenopausal females and age-matched males. current exercise guidelines appear inadequate to ameliorate this increased risk and higher intensity exercise may be necessary. oral inorganic nitrate supplementation enhances both exercise performance and cvd risk profile in several clinical conditions. however, the effects of this intervention in post-menopausal females is unexplored.

the purpose of this study is to determine whether acute inorganic nitrate supplementation and exercising at different exercise intensities (high vs moderate) improve vascular health in post-menopausal females.

Eligibility criteria:
inclusion criteria: * post-menopausal female, defined as having not had a menstrual cycle for at least 1 year * greater than age 45 but less than age 75 * sedentary (does not exercise regularly) * no major changes in medication in the last 3 months exclusion criteria: * smokers within last 5 years * weight unstable (loss/gain of more than 3kg in the past 3 months) * any medical condition that prevents the subject from exercising safely * hormone replacement therapy (current or within last 3 months) * currently or recently on vasoactive medications (i.e., calcium channel blockers, statins, ace or renin inhibitors, arbs, nitrates, alpha- or beta-blockers, diuretics, proton pump inhibitors, etc.) * hysterectomy or oophorectomy

Keywords: flow-mediated dilation pulse wave velocity exercise intensity vascular function
effects of trigeminal neurostimulation on heart rate variability: comparing tragus and tongue stimulation.

Conditions: Arousal, Confusional

Summary: this study wants to analyse the effect of trigeminal stimulation on heart rate variability. there are going to be two groups, in the test group it will be administered stimulation of the tongue with tens, while in the control goup tens will be administered at tragus level.

this study analyses the effect of trigeminal stimulation with tens on heart rate variability (hrv). a new intraoral device will be administered on the dorsal surface of the tongue for tens stimulation in the test group. the rmssd, lf, hf and lf/hf will be monitered by photoplethysmographic wave. the results obtained with tongue stimulation will be compared with the results obtained in the control group, where it will be administered tens stimulation at the tragus level. this work sought to assess whether there is a difference in hrv in relation to the site of application of dental ulftens (tragus vs tongue). if effective in reducing the activity of arousal circuits, this tongue-level stimulation technique could have new clinical applications.

Eligibility criteria:
inclusion criteria: * healthy women * age 18-30 years exclusion criteria: * presence of acute and/or chronic cardio-circulatory and respiratory disorders * metabolic and autonomic system disorders * intake of excitatory or inhibiting substances of the peripheral and central nervous system * presence of generalised anxiety and/or panic attacks or mood disorders.

Keywords: trigeminal electrical stimulation ulftens heart rate variability tragus tongue
improving follow up care for people after minor stroke

Conditions: Stroke, Acute

Summary: the goal of this feasibility study is to ascertain if this follow-up programme of care can feasibly be implemented within a healthcare system with people after minor stroke. the main feasibility questions are: i) to establish recruitment uptake ii) to establish treatment adherence iii) to determine participant retention. participants will be randomly allocated to the intervention and control group. those in the intervention group will receive a follow-up telephone call at two weeks after discharge and a second follow-up appointment at six weeks after discharge. outcome measures will be taken at twelve weeks after discharge.


Eligibility criteria:
inclusion criteria: * adult ≥18 * clinical or radiological diagnosis of minor stroke from a stroke consultant. * admitted to hasu or seen in rapid assessment/tia clinic. * pre-admission mrs of 0-3 with no formal package of care prior to stroke. * discharge mrs of 0-3. * no onward referral to community therapy team or for package of care. * has capacity to consent. exclusion criteria: * any serious co-morbidities that would impact a person's ability to participate in the follow-up appointments and outcome measurement. * insufficient english to engage in intervention and outcome measures and no family or friends to support with this. * not resident in england. * pregnant women.

Keywords: secondary prevention adjustment to life after stroke hidden impairments cognition mood fatigue
ever/tmc mutation as marker of the risk of cutaneous carcinoma in immunosuppressed patients

Conditions: Immunosuppression; Neoplasm

Summary: detection of mutation / specific polymorphism of the ever/tmc6 and/or ever/tmc8 gen.

correlation between possibly detected mutation/specific polymorphism and kind and number of neoplasm, age of patients, uv burden, duration and kind of immunosuppression.

Eligibility criteria:
inclusion criteria: * patients in an immunosuppressive condition either by immunosuppressants or by hiv infection exclusion criteria: * written informed consent not given
levothyroxine for children with euthyroid sick syndrome

Conditions: Euthyroid Sick Syndrome

Summary: the purpose of this study is to determine whether levothyroxine is effective and safe in the treatment of children with euthyroid sick syndrome, hospitalized in a pediatric intensive care unit.

children with euthyroid sick syndrome, hospitalized in a pediatric intensive care unit, will be randomised to receive either levothyroxine or placebo, to determine if it diminishes mortality.

Eligibility criteria:
inclusion criteria: * all children aged 1 month to 17 years. * admitted to pediatric intensive care unit. * tsh and thyroid hormones below age specific levels. exclusion criteria: * known thyroid condition. * brain death. * gut conditions that contraindicate oral route. * readmissions to intensive care unit.

Keywords: euthyroid sick syndromes thyroxine intensive care
doppler evaluation in ra patients after adalimumab.

Conditions: Rheumatoid Arthritis

Summary: the purpose is to study the relationship between ra disease activity based on doppler quantification and the subsequent clinical response (eular response) to treatment with adalimumab during 12 months. the purpose is also to compare the doppler quantification with conventional clinical methods and semiquantitative doppler assessment.


Eligibility criteria:
inclusion criteria: * adult patient (\> 18 years of age), male or female * rheumatoid arthritis according to the 1987 acr or 2010 eular/acr classification criteria * moderate to high disease activity * ongoing anti-rheumatic treatment with dmard, with stable dosage during the last 3 months, and being a candidate for anti-tnf add-on therapy or ongoing treatment with first anti-tnf therapy and being a candidate for switch to another anti-tnf therapy * women with child-bearing potential: use of an adequate method of contraception to avoid pregnancy throughout the study * signed informed consent \*signed informed consent must be obtained before any study specific procedures take place. exclusion criteria: * biologic treatment with adalimumab before inclusion * two or more ongoing biologic treatments before inclusion * treatment with other biologic treatment than anti-tnf therapy before inclusion * any contraindication for treatment with adalimumab * intraarticular corticosteroid injection during the last 4 weeks before each follow-up visit * positive for tuberculosis or hepatitis b. * ongoing pregnancy or lactation
icotinib in previously treated non/light-smoking patients with advanced squamous cell lung cancer

Conditions: Squamous Cell Carcinoma of Lung

Summary: this study is designed to evaluate the efficacy of icotinib at routine dose in previously treated non/light-smoking patients with advanced squamous cell lung cancer.

this study is designed to evaluate the efficacy of icotinib at routine dose in previously treated non/light-smoking patients with advanced squamous cell lung cancer. an objective response (or) was defined as a patient having a best overall response of either complete response (cr) or partial response (pr) according to response evaluation criteria in solid tumors, confirmed at least 28 days following the date of the initial response.

Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed metastatic or recurrent squamous cell lung cancer from the primary lesion and/or lymph nodes, stage iiib or iv patients with non-smoking or light-smoking history. * failure of at least 1, and no more than 2, prior chemotherapy regimens for advanced disease (either due to progressive disease or toxicity). * have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as \>= 20 mm with conventional techniques or as \>= 10 mm with spiral ct scan. * be \>= 18 years of age. * expected survival period over 12 weeks; * ecog ps 0-2. adequate organ system function as defined within the protocol. * patients with a history of cns metastases or cord compression are allowed if they have been definitively treated and are clinically stable. * consent compliance research plan and follow-up process, and be able to carry out oral therapy; provision of written informed consent. * in women of childbearing age, must be in before starting treatment within 7 day of urine pregnancy test and the result is negative, and not in the lactation period, and reproductive age men and women prior to entry into the study, the research process until 90 days after stopping all agree to use reliable methods of contraception; * weight loss =\< 10% in past 6 months. * adequate tumor tissue for detection of molecular biomarkers. exclusion criteria: * patients who have previously received treatment with egfr-tkis. * concomitant treatment with any other experimental drug under investigation or anti-tumor therapy; * symptomatic cns metastases or newly diagnosed cns metastases that have not yet been definitively treated with radiation and/or surgery. * known severe hypersensitivity to icotinib or any of the excipients of this product. * presence of uncontrolled pleural effusion or/and peritoneal effusion; * evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the study. * past or current history of neoplasm (other than the entry diagnosis) in past 5 years, with the exception of treated basal cell carcinoma or carcinoma in situ of the cervix, or other cancers cured by local therapy alone. * women who are lactating.or have positive pregnancy test.

Keywords: icotinib, scc
ibuprofen and neural mobilization treatment in carpal tunnel syndrome.

Conditions: Carpal Tunnel Syndrome; Ibuprofen; Pain Management; Pain, Chronic

Summary: in the present investigation, the pain reduction effect of median nerve neural mobilization and oral ibuprofen treatments will be compared to those produced by the absence of treatment, in subjects who suffer the signs and symptoms of carpal tunnel syndrome.

the present randomized clinical trial will perform a comparison of the pain reduction effects produced by median nerve neural mobilization and oral ibuprofen treatments to the total lack of treatment in subjects diagnosed with carpal tunnel syndrome. effects over the functionality of the affected upper limb will be evaluated and compared. subjects will be invited to participate and randomly allocated to 3 different groups.

Eligibility criteria:
inclusion criteria: * participants must be medically diagnosed with unilateral carpal tunnel syndrome (with confirmative electrodiagnostic findings). * full understanding of written and spoken spanish (language). * participants must freely consent to participate. * the presence of positive phalen and tinel signs. * the presence of carpal tunnel syndrome signs and symptoms. exclusion criteria: * the lack to meet inclusion criterions, * the presence of cognitive impairment, * tumors * cancer * upper limb surgery or trauma * pregnancy * deformities of the (affected) upper limb, * recent skin injuries or infections (in the affected upper limb) * autoimmune inflammatory conditions or flu type symptoms * allergy (or contraindication) to non steroidal anti inflammatory drugs (nsaid) * participants must not be (during the present investigation) under any type of pain reducing treatment (conservative, homeopathic, invasive or not invasive).
quality of life in asthma and rhinitis allergic with singulair (0476-365)

Conditions: Asthma; Rhinitis Allergic

Summary: allow physicians not familiar with anti-leukotriene based therapy to test it


Eligibility criteria:
inclusion criteria: * establish diagnosis of mild to moderate chronic asthma and/or allergic rhinitis currently on treatment * voluntary acceptance to participate in the study exclusion criteria: * patients with cystic fibrosis * patients with known hypersensitivity to singulair or any of its components * patients with severe chronic asthma
safety study of combining ultrasound microbubbles and chemotherapy to treat malignant neoplasms of digestive system

Conditions: Gastrointestinal Neoplasms

Summary: ultrasonic sonoporation can increase the release of chemotherapeutics, thus increasing the therapeutic effects. the main purpose is to identify the safety of combining ultrasonic microbubbles and chemotherapeutics to treat malignant neoplasms of hepatic metastases from alimentary system and pancreatic carcinoma.

ultrasonic sonoporation can increase the release of chemotherapeutics, thus increasing the therapeutic effects. 1. main purpose 1. to identify the safety of combining ultrasonic microbubbles and chemotherapeutics to treat malignant neoplasms of hepatic metastases from alimentary system and pancreatic carcinoma. 2. to explore the largest mechanical index and ultrasonic treatment time which patients can endure. 2. secondary purpose 1. to observe tumor clinical benefit rate (cr+pr+sd). 2. to evaluate the preliminary effect,such as time to failure(ttf), time to death(ttd)

Eligibility criteria:
inclusion criteria: * pathological diagnosis of liver metastases from alimentary system and pancreatic carcinoma * failed routine chemotherapy * neoplasms can be evaluated by imaging * ecog《2 exclusion criteria: * have systematic chemotherapy in 2 weeks * be allergic to ultrasonic microbubbles and chemotherapeutics * uncontrolled high blood pressure, cardiovascular disease * active bleeding * have serious mental and psychological disease

Keywords: microbubble chemotherapy alimentary